Former Pfizer exec joins Nouscom as CMO

Swiss immuno-oncology firm Nouscom today announced the appointment of Adrian Woolfson as chief medical officer (CMO).

Dr Woolfson’s appointment brings to Nouscom over a decade of extensive and broad experience in leading clinical trials in oncology and hematology in the pharmaceutical industry. At Nouscom, Dr Woolfson will play a key role in leading the company’s clinical development of its neoantigen off-the-shelf vaccine targeting tumors associated with Microsatellite Instability (MSI), as well as the personalized neoantigen vaccines and oncolytic virus programs.

Dr Woolfson joins Nouscom from US pharma giant Pfizer (NYSE: PFE) where he most recently served as global clinical leader early and late stage immuno-oncology/hematology and was responsible for building a diverse portfolio of monotherapy and combination studies for Pfizer’s PD-L1 inhibitor Bavencio and 4-1BB agonist utomilumab. Pfizer is still investigating utomilumab in both hematologic cancers and solid tumors as a single agent and in combination with other anti-cancer therapies.